anythingnonidin

Yes, exactly. Psychedelics have been described as "nonspecific amplifiers".

A hypothesis I have is that therapists, and their patients, already know many of the things that'll help make them happier - but the patient isn't doing them, because they lack the motivation, or they lack the belief that they're capable of making and sticking with those changes, so why bother trying.

Doing a psychedelic trip in that therapeutic context seems to make the patient motivated to make the changes that they already logically knew would be helpful, and the trip in this context makes them believe they're capable of making and sticking with those changes - so, then they end up making those changes.

Not true.

Thiel backed COMPASS Pathways which got breakthrough status last year. The Usona Institute, which just got breakthrough status this month, also for a use of psilocybin, is to my knowledge not supported by Thiel.

> Back in late 2018, the FDA granted Breakthrough Therapy status to the ongoing work from COMPASS Pathways investigating psilocybin, the key psychoactive compound in magic mushrooms, as a therapy for treatment-resistant depression. A large, multi-center Phase 2 trial spanning the US, UK and Europe is currently underway testing a variety of dosing strategies.

> This new FDA Breakthrough Therapy approval focuses on a seven-site, Phase 2 trial currently underway in the United States. Coordinated by a non-profit research organization called the Usona Institute, the trial is exploring the antidepressant properties of a single psilocybin dose in treating patients with major depressive disorder.

Dang, perhaps change the title on this to reflect the title of the post? That said, HPPD is an important topic.

> Otherwise please use the original title, unless it is misleading or linkbait; don't editorialize.